<DOC>
	<DOCNO>NCT00356447</DOCNO>
	<brief_summary>The study evaluate Chinese post-menopausal woman combination drospirenone 2 mg estradiol 1 mg treatment climacteric symptom , hot flush ( vasomotor symptom ) uro-genital complaint .</brief_summary>
	<brief_title>Safety/Efficacy Study Drospirenone/Estradiol Treat Postmenopausal Chinese Women With Vasomotor Symptoms .</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer HealthCare AG , Germany . Bayer HealthCare AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<criteria>Chinese postmenopausal woman moderate severe vasomotor symptom History steroid hormone dependent malignant disease Known suspect malignant premalignant disease Current history severe heart , liver , renal , psychiatric disease Hyperlipemia</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>